<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cindy Simoens</style></author><author><style face="normal" font="default" size="100%">Ivana Gorbaslieva</style></author><author><style face="normal" font="default" size="100%">Gheit, Tarik</style></author><author><style face="normal" font="default" size="100%">Holzinger, Dana</style></author><author><style face="normal" font="default" size="100%">Lucas, Eric</style></author><author><style face="normal" font="default" size="100%">Ridder, Ruediger</style></author><author><style face="normal" font="default" size="100%">Rehm, Susanne</style></author><author><style face="normal" font="default" size="100%">Peter Vermeulen</style></author><author><style face="normal" font="default" size="100%">Martin Lammens</style></author><author><style face="normal" font="default" size="100%">Olivier Vanderveken</style></author><author><style face="normal" font="default" size="100%">Kumar, Rekha Vijay</style></author><author><style face="normal" font="default" size="100%">Gangane, Nitin</style></author><author><style face="normal" font="default" size="100%">Alessandro Caniglia</style></author><author><style face="normal" font="default" size="100%">Maffini, Fausto</style></author><author><style face="normal" font="default" size="100%">Maria Belén Lloveras Rubio</style></author><author><style face="normal" font="default" size="100%">Anantharaman, Devasena</style></author><author><style face="normal" font="default" size="100%">Chiocca, Susanna</style></author><author><style face="normal" font="default" size="100%">Brennan, Paul</style></author><author><style face="normal" font="default" size="100%">Madhavan R Pillai</style></author><author><style face="normal" font="default" size="100%">Radhakrishna, Madhavan</style></author><author><style face="normal" font="default" size="100%">Bogers, Johannes</style></author><author><style face="normal" font="default" size="100%">Pawlita, Michael</style></author><author><style face="normal" font="default" size="100%">Tommasino, Massimo</style></author><author><style face="normal" font="default" size="100%">M. Arbyn</style></author><author><style face="normal" font="default" size="100%">HPV-AHEAD study group</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">HPV DNA genotyping, HPV E6*I mRNA detection, and p16INK4a/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Epidemioly</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Alphapapillomavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Cyclin-Dependent Kinase Inhibitor p16</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Head and Neck Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Head and neck neoplasms; Human papillomavirus; Human papillomavirus DNA tests; mRNA; p16(INK4a)</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Ki-67 Antigen</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Oncogene Proteins, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Papillomavirus Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">Staining and Labeling</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">jun 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">72</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;The main risk factors for head and neck cancer (HNC) are tobacco and alcohol use. However, an important fraction of oropharyngeal cancer (OPC) is caused by human papillomaviruses (HPV), a subgroup with increasing incidence in several western countries.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;As part of the HPV-AHEAD study, we assessed the role of HPV infection in 772 archived tissue specimens of Belgian HNC patients: 455 laryngeal (LC), 106 oral cavity (OCC), 99 OPC, 76 hypopharyngeal (HC), and 36 unspecified parts of the head and neck. All specimens were tested for HPV DNA (21 genotypes); whereof all HPV DNA-positives, all HPV DNA-negative OPCs and a random subset of HPV DNA-negatives of the other HNC-sites were tested for the presence of type-specific HPV RNA and p16 over-expression.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The highest HPV DNA prevalence was observed in OPC (36.4 %), and was significantly lower (p &amp;lt; 0.001) in the other HNCs (OCC:7.5 %, LC:6.6 %). HPV16 was the most common HPV-genotype in all HNCs. Approximately 83.0 % of the HPV DNA-positive OPCs tested HPV RNA or p16-positive, compared to about 37.5 % and 44.0 % in OCC and LC, respectively. Estimation of the attributable fraction of an HPV infection in HNC was very similar for HPV RNA or p16 in addition to DNA-positivity; with 30 % for OPC, and 3 % for OCC and LC.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;Our study confirms the heterogeneity of HPV DNA prevalence across anatomical sites in HNC, with a predominance of HPV16 in all sites. The estimated proportion of HPV-driven HNC in Belgium, during the period 1980-2014, was 10 times higher in OPC compared to OCC and LC.&lt;/p&gt;
</style></abstract></record></records></xml>